Composite Inflammatory Score for Predicting Progression-Free Survival in Metastatic Clear Cell Renal Cell Carcinoma Treated With First-Line Toripalimab Plus Axitinib.
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.